Aetna commends FDA's decision on hydroxyprogesterone caproate

The United States Food and Drug Administration today announced that specialty pharmacies can continue compounding 17P (hydroxyprogesterone caproate) based on a valid prescription for an individually identified patient.

"Today's FDA decision is an outstanding win for women and their at-risk babies who may have lost access to a safe and cost-effective treatment to help prevent preterm birth. Aetna has championed the need to provide 17P at an affordable price so that pregnant women would not face a 100-fold increase in treatment cost. The FDA's decision is well-reasoned and helps keep quality health care more affordable," said Lonny Reisman, M.D., Aetna chief medical officer.